UNSPSC 51281818: Doxorubicin hydrochloride

This classification denotes a doxorubicin preparation with the molecular formula C27H29NO11.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82F2G7BL4E, chemically known as 3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-naphthacenyl 3-amino-2,3,6-trideoxyhexopyranoside but more generally known as doxorubicin hydrochloride, which bears US NIH Compound Identifier 1691.

UNSPSC 51281818 Doxorubicin hydrochloride is a Commodity code that does not align with the actual scope of recent state and local procurement activity posted under this code. The recent opportunities tagged to this code solicit naloxone and drug deactivation systems, multi-source generic pharmaceuticals and OTC products, medical and first aid supplies for emergency response, and direct-to-manufacturer prescription program capabilities — none of which are doxorubicin hydrochloride, a specific chemotherapy drug. The mismatch between the code's nominal scope and what state and local governments are actually buying under it suggests a tagging error in the source data rather than legitimate procurement activity for this particular pharmaceutical product line.

Recent activity shows issuing bodies across health departments, cooperative purchasing alliances, and municipal fire rescue divisions posting opportunities that fall under broader pharmaceutical supply, emergency medical equipment, and pharmacy benefit management categories. Geographically, the sample includes Florida (Seminole County), Texas (Health and Human Services Commission), Minnesota (MMCAP multi-state cooperative), Oregon (MMCAP participant), and Florida again (City of Tampa). Because the code does not reflect what is actually being procured, assessment of market activity, pricing strategy, or vendor positioning under UNSPSC 51281818 itself is not supported by these records.